Biotech Values

[genisi]

Bapineuzumab - IV every 13 weeks is indeed the less frequent IV dosing but Wyeth/Elan have a subcutaneous formulation (in phase II), which uses weekly injections and Bapineuzumab might end up with this formulation in order to reduce AE.